Chargement en cours...
Use of anti-TNF drug levels to optimise patient management
Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab pegol and golimumab, have been proven to be effective for the treatment of patients with Crohn's disease and ulcerative colitis. However, 10%–30% of patients with inflammatory bowel disease (IBD) show no i...
Enregistré dans:
| Publié dans: | Frontline Gastroenterol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5369499/ https://ncbi.nlm.nih.gov/pubmed/28839870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/flgastro-2016-100685 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|